Bacoba AG

Bacoba AG is a Swiss biopharmaceutical company that develops novel dermatological products based on skin-penetrating peptides. The drug candidate lefleuganan is currently in the clinical trial phase and is being developed as a new first-line therapy for cutaneous leishmaniasis. This neglected tropical disease is transmitted by flies and causes chronic, disfiguring skin lesions in millions of people. To date, there are few safe and effective treatment options.